The company’s two largest holders Perceptive Advisors and L1...

The company’s two largest holders Perceptive Advisors and L1 Capital cornerstoned the Placement, each subscribing beyond their existing pro-rata shareholding. Proceeds from the Placement will be used primarily for the clinical development of DurAVRTM, the Company’s 3D single-piece aortic valve for the treatment of aortic stenosis and for general working capital purposes. Participants in the Placement will also receive one attaching unlisted option to acquire an ordinary share in Anteris for each New Share, expiring two years from the date of issue with an exercise price of $29.00 (New Options). Wayne Paterson, Chief Executive Officer and Managing Director, has also entered into a binding agreement to invest in the capital raise on the same terms amounting to $100,008. This investment is subject to shareholder approval and will be considered at the Annual General Meeting.

In case we miss these crucial points.